Peptides / Cagrilintide / United Kingdom

Cagrilintide in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine. Investigational.

As understood at 2026-09-22. Verify with the MHRA.

What Cagrilintide is

Cagrilintide is a long-acting synthetic analogue of amylin, a 37-amino-acid hormone released alongside insulin that slows stomach emptying and signals fullness. Developed by Novo Nordisk, it is mostly studied in combination with semaglutide under the name CagriSema. It is an investigational drug and not yet licensed anywhere.

Full Cagrilintide page: targets and research →

Listed suppliers in the United Kingdom

1 of the 10 suppliers we list in the United Kingdom list Cagrilintide. Listed, not endorsed: each row is the supplier’s own stated terms.

Bluewell Peptides United Kingdom All Bluewell products are supplied strictly for laboratory research use only. They are not intended for human consumption, medical use, therapeutic use, diagnostic use, or veterinary use.

Clinical Research

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Garvey WT, Blüher M, Osorto Contreras CK, et al. (REDEFINE 1 Study Group) (2025). New England Journal of Medicine. human adults with overweight or obesity, without diabetes, phase 3a, n=3417

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies MJ, Bajaj HS, Broholm C, et al. (REDEFINE 2 Study Group) (2025). New England Journal of Medicine. human adults with overweight or obesity and type 2 diabetes, phase 3a, n=1206

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

Petersen J, Merrild C, Holm SK, et al. (2026). Nature Metabolism. animal diet-induced obese male rats